Erasca reports RAS cancer drug data after legal threat from Revolution

April 27, 2026 04:01 PM EDTUpdated 04:16 PM R&DLaw A show­down in the clin­ic and the courts: Eras­ca and Rev­o­lu­tion bat­tle over RAS Nicole DeFeudis Senior Reporter Max Bayer Senior Reporter Af­ter a new drug from Rev­o­lu­tion Med­i­cines reignit­ed hopes for treat­ing pan­cre­at­ic can­cer, a ri­val com­pound from Eras­ca — which re­leased ear­ly-stage da­ta on Mon­day — could … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER